...
首页> 外文期刊>The Biochemical Journal >Chemical synthesis and characterization of a new quinazolinedione competitive antagonist for strigolactone receptors with an unexpected binding mode
【24h】

Chemical synthesis and characterization of a new quinazolinedione competitive antagonist for strigolactone receptors with an unexpected binding mode

机译:具有意外结合模式的胞内酮受体新喹唑啉二极管竞争性拮抗剂的化学合成与表征

获取原文
获取原文并翻译 | 示例

摘要

Strigolactones (SLs) are multifunctional plant hormones regulating essential physiological processes affecting growth and development. In vascular plants, SLs are recognized by alpha/beta hydrolase-fold proteins from the D14/DAD2 (Dwarf14/Decreased Apical Dominance 2) family in the initial step of the signaling pathway. We have previously discovered that N-phenylanthranilic acid derivatives (e.g. tolfenamic acid) are potent antagonists of SL receptors, prompting us to design quinazolinone and quinazolinedione derivatives (QADs and QADDs, respectively) as second-generation antagonists. Initial in silico docking studies suggested that these compounds would bind to DAD2, the petunia SL receptor, with higher affinity than the first-generation compounds. However, only one of the QADs/QADDs tested in in vitro assays acted as a competitive antagonist of SL receptors, with reduced affinity and potency compared with its N-phenylanthranilic acid 'parent'. X-ray crystal structure analysis revealed that the binding mode of the active QADD inside DAD2' s cavity was not that predicted in silico, highlighting a novel inhibition mechanism for SL receptors. Despite a similar to 10-fold difference in potency in vitro, the QADD and tolfenamic acid had comparable activity in planta, suggesting that the QADD compensates for lower potency with increased bioavailability. Altogether, our results establish this QADD as a novel lead compound towards the development of potent and bioavailable antagonists of SL receptors.
机译:杂曲酮(SLS)是多功能植物激素调节影响生长和发育的必要生理过程。在信号通路的初始步骤中,在血管植物中,SLS由来自D14 / DAD2(DWARF14 /降低的顶端优势2)家族的α/β水解酶折叠蛋白识别。我们以前发现N-苯基吡啶酸衍生物(例如脱酚酸)是SL受体有效的拮抗剂,促使我们设计为第二代拮抗剂的喹唑啉酮和喹唑啉二酮衍生物(QADS和CADDS)。 Silico对接研究中的初始表明,这些化合物将与DAD2,Petunia SL受体结合,具有比第一代化合物更高的亲和力。然而,在体外测定中测试的QADS / QADDS中的一个作用为SL受体的竞争性拮抗剂,与其正苯壬酸“父母”相比,具有降低的亲和力和效力。 X射线晶体结构分析显示,DAD2腔内的活性QADD的结合模式在硅中的预测不预测,突出了SL受体的新抑制机制。尽管存在类似于体外效力的10倍差异,但QADD和脱酚酸在Planta中具有相当的活性,这表明QADD可补偿较低的生物利用度。完全,我们的结果将该QADD作为一种新型铅化合物,以发展有效和生物可利用者的SL受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号